• Sonuç bulunamadı

The antiplatelet activity of escherichia coli lipopolysaccharide is mediated through a nitric oxide/cyclic GMP pathway.

N/A
N/A
Info
İndir
Protected

Academic year: 2021

Share "The antiplatelet activity of escherichia coli lipopolysaccharide is mediated through a nitric oxide/cyclic GMP pathway."

Copied!
1
0
0

Yükleniyor.... (view fulltext now)

Şimdi indir ( 1 sayfa )

Tam metin

(1)

The antiplatelet activity of escherichia coli

lipopolysaccharide is mediated through a

nitric oxide/cyclic GMP pathway

蘇慶華;李玲玟

Sheu JR;Hung WC;Su CH;Lin CH;Lee LW;Lee YM and

Yen MH

摘要

Abstract

In this study, Escherichia coli LPS dose-dependently (100-500 microg/ml) and

time-dependently (10-60 min) inhibited platelet aggregation in human and rabbit platelets stimulated by agonists. LPS also dose-dependently inhibited the intracellular Ca2+ mobilization in human platelets stimulated by collagen. In addition, LPS (200 and 500 microg/ml) significantly increased the formation of cyclic GMP but not cyclic AMP in platelets. LPS (200 microg/ml) significantly increased the production of nitrate within a 10-min incubation period. Furthermore, LPS also dose-dependently inhibited platelet aggregation induced by PDBu (30 nmol/l), a protein kinase C activator. These results indicate that the antiplatelet activity of E. coli LPS may be involved in the activation of a nitric oxide/cyclic GMP pathway in platelets, resulting in inhibition of platelet aggregation. Therefore, LPS-mediated alteration of platelet function may contribute to bleeding

Referanslar

Şimdi indir ( PDF - 1 sayfa - 39.29 KB )

Benzer Belgeler

Role of nitric oxide in the pathogenesis of renalhemodynamic changes in diabetes

Renal blood flow (RBF), urinar output rate, creatinine clearence and urinary excretion of creatinine , protein, glucose, potassium, sodium and phosphorus excretions in diabetic

Anesthetic inhibition of nitric oxide biosynthesis PROPOFOL studies of the effect

The above results, that LPS activates the macrophage, so that iNOS mRNA and iNOS protein expression increased, thereby enabling larger downstream NO production, and propofol

Alpha-naphthoflavone, a potent antiplatelet flavonoid, is mediated through inhibition of phospholipase C activity and stimulation of cyclic GMP formation.

(1) alpha-NF may inhibit the activation of phospholipase C, followed by inhibition of phosphoinositide breakdown, protein kinase C activation, and thromboxane A(2) formation,

The Antiplatelet activity of ketamine is mediated through suppression of phosphoinositide breakdown and an increase in cyclic GMP.

coli LPS may be involved in the activation of a nitric oxide/cyclic GMP pathway in platelets, resulting in inhibition of platelet aggregation. Therefore, LPS-mediated alteration

The antiplatelet activity of PMC, a potent a-tocopherol analogue, is mediated through inhibition of cyclooxygenase. Br.

Moreover, PMC (25, 100, and 200 μM) did not affect the thromboxane synthetase activity of aspirin-treated platelet microsomes.PMC (10 and 25μM) markedly inhibited the

The antiplatelet activity of rutaecarpine, an alkaloid isolated from Evodia rutaecarpa, is mediated through inhibition of phospholipase C.

In platelet suspen- hand, various concentrations of rutaecarpine (50,sions (4.53108/ml), rutaecarpine (100 and 200 mM) 100, and 200 mM) dose-dependently inhibited did not

Antiplatelet activity of staphylococcus aureus lipoteichoic acid is mediated through a cyclic AMP pathway

This phos- are currently caused by Gram-positive organisms, phorylation was dose dependently inhibited by and that the incidence of Gram-positive sepsis LTA (0.5 and 1.0

The antiplatelet activity of tetramethylpyrazine is mediated through activation of NO synthase.

Furthermore, TMPZ concentration (50 and 200m M)- and time (15 and 30 min)-dependently triggered endothelial- type constitutive nitric oxide synthase (ecNOS) protein expression